Lihong TaoPadma Priya TogarratiKyung Dal ChoiKran SuknunthaWisconsin National Primate Research CenterBlood Systems Research InstituteUniversity of Minnesota Twin CitiesMahidol University2018-12-212019-03-142018-12-212019-03-142017-01-01Journal of Stem Cells and Regenerative Medicine. Vol.13, No.2 (2017), P75-P79097371542-s2.0-85038914094https://repository.li.mahidol.ac.th/handle/20.500.14594/42032© Journal of Stem Cells and Regenerative Medicine. All rights reserved. Human embryonic stem cell (hESC)-derived hematopoietic stem/progenitor cells hold tremendous potential as alternative cell sources for the treatment of various hematological diseases, drug discovery and toxicological screening. However, limited number of hematopoietic stem/progenitor cells generated from the differentiation of hESCs hinders their downstream applications. Here, we show that aryl hydrocarbon receptor antagonist StemRegenin 1 (SR1) selectively promotes expansion of hESC-derived lin-CD34+hematopoietic progenitors in a concentration-dependent manner. The colony-forming cell (CFC) activity was found to be enriched in the CD34+cells that were expanded with SR1; however, these cells have less colony-forming activity as compared to unexpanded cells (1,338 vs. 7 of CD34+cells to form 1 colony, respectively). Interestingly, SR1 showed a bipotential effect on the proliferation of CD34 negative population, that is low dose of SR1 (1 μM) enhanced cell proliferation, whereas it was repressed at higher doses (>5 μM). In summary, our results suggest that SR1 has the potential to facilitate expansion of hESC-derived lin-CD34+hematopoietic progenitors, which further retain the potential to form multilineage hematopoietic colonies.Mahidol UniversityBiochemistry, Genetics and Molecular BiologyArticleSCOPUS